Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer

T. Gamucci, A. M. D'Ottavio, E. Magnolfi, M. Barduagni, A. Vaccaro, I. Sperduti, L. Moscetti, F. Belli, L. Meliffi

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

This study was designed to evaluate the efficacy and tolerability of a weekly schedule of epirubicin in combination with docetaxel in the first-line treatment of patients with metastatic breast cancer (MBC). A total of 43 women with MBC not previously treated with chemotherapy for metastatic disease received weekly epirubicin 25 mg -2 and docetaxel 25 mg m -2 for a maximum of five cycles (total cumulative epirubicin dose of ≤900 mg m-2). Dose reduction was not permitted. Objective response and evaluation of toxicity profile were the primary study end points; time to progression and overall survival were secondary end points. Patients were followed for a median of 21 (4-38) months. Analysis was by intent to treat; 33 patients completed five cycles of therapy, and the median dose of epirubicin administered to the 43 patients was 23 mg m-2. Twenty-five patients (58%) achieved a partial response and one (2%) achieved a complete response. An additional 12 patients (28%) had stable disease. The median time to progression was 11 months (95% confidence intervals (CI) 7-14) overall, and 13 months (95% CI 12-14) in the 26 patients who responded to treatment. Median overall survival was 25 months for responders and 14 months for nonresponders. Grade 3/4 neutropenia occurred in 16% of patients and in 6% of cycles. One patient developed cardiac toxicity (20% reduction in left ventricular ejection fraction). The combination of epirubicin plus docetaxel is highly active in MBC, with a manageable toxicity profile. Such a weekly schedule might provide a valuable treatment option for MBC.

Original languageEnglish
Pages (from-to)1040-1045
Number of pages6
JournalBritish Journal of Cancer
Volume97
Issue number8
DOIs
Publication statusPublished - Oct 22 2007

Fingerprint

docetaxel
Epirubicin
Breast Neoplasms
Therapeutics
Appointments and Schedules
Confidence Intervals
Survival
Neutropenia

Keywords

  • Chemotherapy
  • Metastatic breast cancer
  • Three week schedule
  • Weekly docetaxel
  • Weekly epirubicin
  • Weekly schedule

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gamucci, T., D'Ottavio, A. M., Magnolfi, E., Barduagni, M., Vaccaro, A., Sperduti, I., ... Meliffi, L. (2007). Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer. British Journal of Cancer, 97(8), 1040-1045. https://doi.org/10.1038/sj.bjc.6603982

Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer. / Gamucci, T.; D'Ottavio, A. M.; Magnolfi, E.; Barduagni, M.; Vaccaro, A.; Sperduti, I.; Moscetti, L.; Belli, F.; Meliffi, L.

In: British Journal of Cancer, Vol. 97, No. 8, 22.10.2007, p. 1040-1045.

Research output: Contribution to journalArticle

Gamucci, T, D'Ottavio, AM, Magnolfi, E, Barduagni, M, Vaccaro, A, Sperduti, I, Moscetti, L, Belli, F & Meliffi, L 2007, 'Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer', British Journal of Cancer, vol. 97, no. 8, pp. 1040-1045. https://doi.org/10.1038/sj.bjc.6603982
Gamucci T, D'Ottavio AM, Magnolfi E, Barduagni M, Vaccaro A, Sperduti I et al. Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer. British Journal of Cancer. 2007 Oct 22;97(8):1040-1045. https://doi.org/10.1038/sj.bjc.6603982
Gamucci, T. ; D'Ottavio, A. M. ; Magnolfi, E. ; Barduagni, M. ; Vaccaro, A. ; Sperduti, I. ; Moscetti, L. ; Belli, F. ; Meliffi, L. / Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer. In: British Journal of Cancer. 2007 ; Vol. 97, No. 8. pp. 1040-1045.
@article{1778bba19883446da8e66a97e42f79ec,
title = "Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer",
abstract = "This study was designed to evaluate the efficacy and tolerability of a weekly schedule of epirubicin in combination with docetaxel in the first-line treatment of patients with metastatic breast cancer (MBC). A total of 43 women with MBC not previously treated with chemotherapy for metastatic disease received weekly epirubicin 25 mg -2 and docetaxel 25 mg m -2 for a maximum of five cycles (total cumulative epirubicin dose of ≤900 mg m-2). Dose reduction was not permitted. Objective response and evaluation of toxicity profile were the primary study end points; time to progression and overall survival were secondary end points. Patients were followed for a median of 21 (4-38) months. Analysis was by intent to treat; 33 patients completed five cycles of therapy, and the median dose of epirubicin administered to the 43 patients was 23 mg m-2. Twenty-five patients (58{\%}) achieved a partial response and one (2{\%}) achieved a complete response. An additional 12 patients (28{\%}) had stable disease. The median time to progression was 11 months (95{\%} confidence intervals (CI) 7-14) overall, and 13 months (95{\%} CI 12-14) in the 26 patients who responded to treatment. Median overall survival was 25 months for responders and 14 months for nonresponders. Grade 3/4 neutropenia occurred in 16{\%} of patients and in 6{\%} of cycles. One patient developed cardiac toxicity (20{\%} reduction in left ventricular ejection fraction). The combination of epirubicin plus docetaxel is highly active in MBC, with a manageable toxicity profile. Such a weekly schedule might provide a valuable treatment option for MBC.",
keywords = "Chemotherapy, Metastatic breast cancer, Three week schedule, Weekly docetaxel, Weekly epirubicin, Weekly schedule",
author = "T. Gamucci and D'Ottavio, {A. M.} and E. Magnolfi and M. Barduagni and A. Vaccaro and I. Sperduti and L. Moscetti and F. Belli and L. Meliffi",
year = "2007",
month = "10",
day = "22",
doi = "10.1038/sj.bjc.6603982",
language = "English",
volume = "97",
pages = "1040--1045",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer

AU - Gamucci, T.

AU - D'Ottavio, A. M.

AU - Magnolfi, E.

AU - Barduagni, M.

AU - Vaccaro, A.

AU - Sperduti, I.

AU - Moscetti, L.

AU - Belli, F.

AU - Meliffi, L.

PY - 2007/10/22

Y1 - 2007/10/22

N2 - This study was designed to evaluate the efficacy and tolerability of a weekly schedule of epirubicin in combination with docetaxel in the first-line treatment of patients with metastatic breast cancer (MBC). A total of 43 women with MBC not previously treated with chemotherapy for metastatic disease received weekly epirubicin 25 mg -2 and docetaxel 25 mg m -2 for a maximum of five cycles (total cumulative epirubicin dose of ≤900 mg m-2). Dose reduction was not permitted. Objective response and evaluation of toxicity profile were the primary study end points; time to progression and overall survival were secondary end points. Patients were followed for a median of 21 (4-38) months. Analysis was by intent to treat; 33 patients completed five cycles of therapy, and the median dose of epirubicin administered to the 43 patients was 23 mg m-2. Twenty-five patients (58%) achieved a partial response and one (2%) achieved a complete response. An additional 12 patients (28%) had stable disease. The median time to progression was 11 months (95% confidence intervals (CI) 7-14) overall, and 13 months (95% CI 12-14) in the 26 patients who responded to treatment. Median overall survival was 25 months for responders and 14 months for nonresponders. Grade 3/4 neutropenia occurred in 16% of patients and in 6% of cycles. One patient developed cardiac toxicity (20% reduction in left ventricular ejection fraction). The combination of epirubicin plus docetaxel is highly active in MBC, with a manageable toxicity profile. Such a weekly schedule might provide a valuable treatment option for MBC.

AB - This study was designed to evaluate the efficacy and tolerability of a weekly schedule of epirubicin in combination with docetaxel in the first-line treatment of patients with metastatic breast cancer (MBC). A total of 43 women with MBC not previously treated with chemotherapy for metastatic disease received weekly epirubicin 25 mg -2 and docetaxel 25 mg m -2 for a maximum of five cycles (total cumulative epirubicin dose of ≤900 mg m-2). Dose reduction was not permitted. Objective response and evaluation of toxicity profile were the primary study end points; time to progression and overall survival were secondary end points. Patients were followed for a median of 21 (4-38) months. Analysis was by intent to treat; 33 patients completed five cycles of therapy, and the median dose of epirubicin administered to the 43 patients was 23 mg m-2. Twenty-five patients (58%) achieved a partial response and one (2%) achieved a complete response. An additional 12 patients (28%) had stable disease. The median time to progression was 11 months (95% confidence intervals (CI) 7-14) overall, and 13 months (95% CI 12-14) in the 26 patients who responded to treatment. Median overall survival was 25 months for responders and 14 months for nonresponders. Grade 3/4 neutropenia occurred in 16% of patients and in 6% of cycles. One patient developed cardiac toxicity (20% reduction in left ventricular ejection fraction). The combination of epirubicin plus docetaxel is highly active in MBC, with a manageable toxicity profile. Such a weekly schedule might provide a valuable treatment option for MBC.

KW - Chemotherapy

KW - Metastatic breast cancer

KW - Three week schedule

KW - Weekly docetaxel

KW - Weekly epirubicin

KW - Weekly schedule

UR - http://www.scopus.com/inward/record.url?scp=35348907308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348907308&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6603982

DO - 10.1038/sj.bjc.6603982

M3 - Article

VL - 97

SP - 1040

EP - 1045

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 8

ER -